CorMedix Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	162.5	-17.93	-46.34	-29.7	-28.21	-22.03
Depreciation & Amortization	4.25	0.31	0.07	0.08	0.06	0.13
Stock-Based Compensation	11.44	6.13	5.49	4.07	5.04	2.5
Provision & Write-off of Bad Debts	0.14	0.14	-	-	-	-
Other Operating Activities	-56.7	0.15	0.13	0.12	0.12	0.08
Change in Accounts Receivable	-112.93	-51.79	-	0.04	-0.04	-0
Change in Inventory	-3.63	-5.49	-2.11	0	0.15	0.15
Change in Accounts Payable	10.97	-2.56	2.08	-0.01	1.08	0.1
Change in Unearned Revenue	-	-	-	-	-	-0
Change in Other Net Operating Assets	62.03	20.43	2.26	1.03	0.65	-2.89
Operating Cash Flow	74.97	-50.61	-38.41	-24.36	-21.16	-21.97
Capital Expenditures	-0.55	-0.12	-0.33	-0.22	-1.43	-0.11
Investment in Securities	-1.48	21.35	-16.73	-3.49	-7.71	7.54
Investing Cash Flow	-312.03	21.23	-17.06	-3.71	-9.13	7.43
Net Debt Issued (Repaid)	149.95	-	-	-	-	-
Issuance of Common Stock	103.27	26.61	56.12	17.9	41.76	40.1
Repurchase of Common Stock	-1.78	-0.29	-0.2	-	-	-
Other Financing Activities	-0.28	-	-	-	-	-
Financing Cash Flow	251.15	26.32	55.92	17.9	41.76	40.1
Foreign Exchange Rate Adjustments	0	-0	0	-0.01	-0.01	0.01
Net Cash Flow	14.09	-3.07	0.45	-10.18	11.45	25.57
Free Cash Flow	74.42	-50.73	-38.74	-24.58	-22.58	-22.08
Free Cash Flow Margin	34.73%	-116.70%	-	-37573.53%	-11826.24%	-9229.69%
Free Cash Flow Per Share	1.03	-0.86	-0.76	-0.61	-0.60	-0.77
Cash Interest Paid	0.03	0.04	0.03	0.03	0.02	0.03
Levered Free Cash Flow	16.7	-44.72	-22.97	-14.03	-12.73	-17.05
Unlevered Free Cash Flow	17.31	-44.7	-22.95	-14.01	-12.72	-17.03
Change in Working Capital	-43.56	-39.41	2.23	1.07	1.84	-2.65

Source: S&P Global Market Intelligence. Standard template. Financial Sources.